Stocks Actavis Inc

  • Stocks closed slightly lower in choppy trading Monday, pulling back after the Dow and S&P 500 hit fresh all-time highs and amid ongoing worries that the Federal Reserve may taper its bond-purchase program.

  • U.S. stock market index futures were slightly lower Monday, after major averages finished higher for the fourth-consecutive week, amid ongoing concerns the Federal Reserve may begin to taper off its quantitative easing program sooner than expected.

  • Warner Chilcott Ltd.'s acne treatment Doryx.

    Generic drugmaker Actavis will buy specialty pharmaceuticals company Warner Chilcott in a stock deal valued at about $8.5 billion.

  • Some of the names on the move ahead of the open.

  • Actavis received and rejected a takeover offer from Mylan last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation said.

  • Some of the names on the move ahead of the open.

  • A proposed merger of Valeant Pharmaceuticals International Inc and Actavis Inc. was put on hold after the two drugmakers failed to agree on terms of a deal.

  • Some of the names on the move ahead of the open.

  • Federal regulators are pressing the Supreme Court to stop big pharmaceuticals from paying generic drug competitors to delay releasing cheaper versions of brand-name drugs.

  • The U.S. Supreme Court building.

    The Supreme Court will hear arguments on Monday over whether big drug companies can settle patent litigation with generic rivals by making deals to keep cheaper products off the market.

  • The Parsippany, N.J.- based company had sued the FDA this summer to gain approval for the drug and sought shared marketing exclusivity for its generic version of the drug. After Watson sued the FDA, the company said Mylan Pharmaceuticals Inc. intervened as a defendant in the action.

  • NEW YORK-- Shares of Mylan Inc. rose to their highest price in almost nine years on Friday after the drugmaker reported higher sales of its EpiPen allergy injection and raised its 2012 guidance. The company said it now expects to earn between $2.50 and $2.60 per share in 2012, about 15 cents per share more than it had expected.

  • PARSIPPANY, N.J.-- Shares of Watson Pharmaceuticals Inc. reached new highs Tuesday after the Federal Trade Commission cleared its acquisition of Swiss drugmaker Actavis Group. Watson and Actavis will sell three approved products to Sandoz, a unit of Novartis AG, including generic versions of the antidepressant Wellbutrin XL and the anxiety drug Ativan.

  • Oct 12- Watson Pharmaceuticals Inc:. *Watson's generic Avaproï¿ ½ receives FDA approval. *Irbesartan tablets USP is the generic equivalent to Sanofi's Avaproï¿ ½.

  • Oct 12- Watson Pharmaceuticals Inc:. *Watson's generic sanctura xrï¿ ½ receives FDA approval. *Says intends to begin shipping the product immediately.

  • Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • Trade of the Day: Watson Pharmaceuticals

    In the generic drug world, Joe Terranova of Virtus Investment Partners, says Watson Pharmaceuticals is "best in breed."

  • BRUSSELS, Oct 8- The following are mergers under review by the European Commission and a brief guide to the EU merger process:. --Private equity firm Carlyle Group LP to buy photo agency Getty Images Inc from private equity firm Hellman& Friedman LLC.

  • Oct 5- Watson Pharmaceuticals Inc:. *Receives approval from European commission for pending actavis acquisition. *Says transaction remains subject to regulatory approval in the United States.

  • BRUSSELS, Oct 5- U.S. drugmaker Watson Pharmaceuticals Inc secured EU regulatory clearance on Friday to buy Swiss peer Actavis Group for at least 4.25 billion euros to reinforce its international reach. It forecast synergies of more than $300 million within three years. The European Commission said in a statement that the deal would not hurt competition.